Merck faces heavy competition in almost every area of brain research, especially from Pfizer, which has been working on substance P blockers for depression and on new, safer antianxiety drugs.
As such, EBPP articulates a decision-making process for integrating multiple streams of research evidence including but not limited to RCTs into the intervention process (p 275).